Investor Day November 2025 Welcome to Investor Day TAMARA GONZALEZ VP, Investor Relations & Communications INVESTOR DAY 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under "Fiscal 2025 Outlook," as well as other statements related to our current bel ...

National Vision (EYE) FY Conference Summary Company Overview - National Vision operates in the optical retail industry, offering three main products: eye exams, eyeglasses, and contact lenses [3][4] - The company is positioned as a low-cost provider in a fragmented market, which generated $70 billion in sales last year across 45,000 retail outlets [4][5] - National Vision has over 1,200 stores and reported $1.8 billion in sales last year [5][6] Key Points and Arguments Business Model and Market Position - National Vision emphasizes its value pricing strategy, catering to a demographic that is increasingly reliant on insurance for eye care [5][6] - The company has the largest collection of employed optometrists in the nation, which is expected to play a larger role in healthcare as demand for eye care services increases [5][6] Post-COVID Transformation - The company faced challenges post-COVID due to a reduction in the availability of medical professionals, impacting the ability to conduct eye exams [7][8] - National Vision implemented a remote medicine approach, allowing optometrists to conduct eye exams from home, which has improved efficiency [9][10] Strategic Initiatives - A new management team was brought in to lead a transformation focused on expanding target demographics, revising pricing strategies, enhancing customer experience, and optimizing cost structures [10][12] - The company aims to increase its addressable market by targeting managed care consumers, progressive lens users, and outside prescription consumers [17][18] Financial Performance - In Q1, National Vision reported a 5.7% increase in net revenue and a 21.8% increase in adjusted operating income [30][31] - The company raised its guidance for 2025, projecting a same-store sales growth of 1.5% to 3.5% and adjusted operating income between $81 million and $92 million [31][33] Marketing and Customer Engagement - National Vision is modernizing its marketing approach to better target its evolving consumer base, moving away from a one-size-fits-all strategy to a more personalized experience [26][27] - The company is enhancing its in-store experience and training staff to better engage with consumers who have insurance benefits [21][22] Product Assortment and Pricing - The company plans to increase the percentage of its frame assortment priced above $99 from 20% to 40% by the end of 2025, aligning with the purchasing power of its target demographic [23][24] - New premium brands are being introduced to attract higher-income consumers [24][25] Additional Important Insights - National Vision conducts over 7 million eye exams annually, with a significant portion of consumers engaging through their online platform [36] - The management team expresses confidence in the company's transformation and growth potential, highlighting a strong organizational culture and commitment to innovation [28][29][35]

Core Viewpoint - National Vision Holdings Inc. has emerged as a significant stock in the market, experiencing a surge of over 40% in the past week, driven by strong earnings and a double upgrade from Bank of America [2][9]. Company Overview - National Vision is valued at $1.5 billion and operates over 1,300 retail optical locations in the U.S., including brands like America's Best Contacts & Eyeglasses and Eyeglass World, providing eye exams, glasses, and contact lenses [3]. Earnings Performance - The company's first-quarter earnings report exceeded expectations, with non-GAAP EPS at 34 cents, beating estimates by 3 cents, and revenue reaching $510.3 million, a nearly 6% increase year-over-year [5]. Strategic Changes - Management attributed the positive results to strategic changes implemented in late 2024, including a new pricing architecture, improved recruitment and retention of optometrists, and new remote exam capabilities [6]. Guidance and Market Reaction - National Vision raised its full-year 2025 guidance, signaling strong future performance, which has contributed to the stock's recent rally [7]. Analyst Upgrades - Bank of America issued a rare double upgrade for National Vision, moving it from Underperform to Buy, with a new price target set at $22, indicating potential for further gains [9]. Future Outlook - Analysts highlight that National Vision's initiatives are effective, with a strong setup for the latter half of 2025, focusing on promotional frame traffic and improved marketing execution [10]. Cost Structure and Risks - Less than 10% of National Vision's cost of goods sold is exposed to China, which mitigates tariff-related risks, and recent pricing changes have improved margins without negatively impacting customer satisfaction [11].

Core Insights - Alcon Inc. is experiencing strong market share gains driven by its innovative product pipeline and focus on research, despite facing challenges from geopolitical pressures and a competitive landscape [1] Group 1: Business Performance - The Surgical segment reported a 5% year-over-year revenue increase in Q4 2024, primarily due to strong international demand for advanced intraocular lenses and equipment [2] - In Vision Care, Alcon is achieving solid growth through strong sales of contact lenses and ocular health products, positioning itself as one of the fastest-growing companies in the sector [3] - Ocular Health continues to perform well, with the Systane family of artificial tears contributing to growth, and the stock has gained 8.4% year-to-date compared to the industry's 4.9% rise [4] Group 2: Challenges and Concerns - Alcon is facing inflationary pressures in electronic components, freight, labor, and materials, which are impacting margins, with net sales costs up 4.2% year-over-year in Q4 [5] - The company is encountering supply chain challenges, particularly with microchips and plastics, which are expected to persist into 2025 [5] - The ophthalmology industry is highly competitive, with Alcon facing competition from both large manufacturers and smaller specialized companies, as well as alternative medical therapies [6] - In the vision care segment, increased competition from Asian contact lens manufacturers is posing significant threats, with a shift in demand towards daily lenses and advanced materials [7]